Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a pioneering commercial-stage biopharmaceutical company that specializes in the discovery, creation, and delivery of transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers. Established in 2015, the company is headquartered in Palo Alto, California. BridgeBio's mission is to address significant unmet medical needs through genetic medicine by leveraging a comprehensive pipeline of development programs that span from early-stage scientific research to late-stage clinical trials.
The company's core focus areas include Mendelian diseases, Genetic Dermatology, Oncology, and Gene Therapy. BridgeBio’s innovative approach involves systematically mapping the genetic disease landscape to identify promising therapeutic assets. Their proprietary platform and management expertise are harnessed to accelerate the development of these early-stage assets into clinically impactful treatments.
BridgeBio’s robust pipeline boasts several notable programs:
- Acoramidis (AG10): Aiming to treat transthyretin amyloid cardiomyopathy (ATTR-CM), this next-generation, orally-administered TTR stabilizer has shown positive results in the Phase 3 ATTRibute-CM trial. The New Drug Application (NDA) for acoramidis has been accepted by the FDA, with a target decision date set for November 29, 2024.
- Infigratinib: Targeting achondroplasia and hypochondroplasia, this FGFR1-3 inhibitor aims to address skeletal dysplasias. The PROPEL 2 Phase 2 trial has demonstrated significant and sustained increases in growth velocity.
- BBP-418: Designed for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), this glycosylation substrate is under Phase 3 trials, with the potential for accelerated approval based on recent interactions with the FDA.
BridgeBio's track record includes successful capital raises, strategic partnerships, and a series of public offerings that have strengthened its financial positioning. The company recently completed a $200 million private financing for its oncology subsidiary, BridgeBio Oncology Therapeutics, to accelerate the development of its precision oncology pipeline.
Key recent developments include:
- The initiation of a comprehensive equity grants program to attract top talent in the biopharmaceutical industry.
- Positive results from multiple clinical trials, including significant improvements in health-related quality of life measures for patients with ATTR-CM treated with acoramidis.
- Ongoing collaborations with global pharmaceutical leaders like Bayer for the commercial development and distribution of key assets in international markets.
BridgeBio remains committed to advancing genetic medicine and delivering groundbreaking therapies to improve patient lives. For more information, visit bridgebio.com and follow them on LinkedIn and Twitter.
Rhea-AI Summary
Invitae (NVTA) announces a partnership with BridgeBio Pharma (BBIO) to advance genetics-based drug discovery for rare diseases. The collaboration aims to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs. Invitae's extensive dataset and analytical capabilities will be combined with BridgeBio's expertise in rare disease research and therapeutic development to support the development of transformative medicines for patients with rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. secures strategic financing of up to $1.25 billion from Blue Owl Capital and CPP Investments to support the anticipated launch of acoramidis, a potential therapy for transthyretin amyloid cardiomyopathy (ATTR-CM). The financing includes $500 million in cash from Blue Owl and CPP Investments, a $450 million credit facility from Blue Owl, and the possibility of an additional $300 million credit facility. The royalty agreement with Blue Owl and CPPIB Credit entails a 5% royalty on future global net sales of acoramidis, capped at 1.9 times the invested capital. The refinancing with Blue Owl extends maturity from 2026 to 2029, providing operational flexibility. The financing positions BridgeBio well to launch acoramidis and accelerate its genetic medicine R&D engine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. (BBIO) announced positive results from its Phase 3 ATTRibute-CM study of acoramidis for patients with ATTR-CM, demonstrating a significant treatment effect with a 1.8 Win Ratio and 80.7% survival rate. Acoramidis was well-tolerated, with no safety concerns identified. BridgeBio submitted a New Drug Application to the FDA and plans to submit marketing authorization applications to additional regulatory bodies in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
Rhea-AI Summary
BridgeBio Pharma, a commercial-stage biopharmaceutical company (Nasdaq: BBIO), granted 66,963 shares of restricted stock units to twenty-five new employees. Vesting of shares will occur on February 16, 2025, with subsequent vesting on a quarterly basis, subject to continued employment. The awards were made under the Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) to present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) has received FDA clearance for the investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and highly potent small molecule direct inhibitor of KRASG12C. The drug is expected to significantly improve outcomes for patients with KRASG12C driven malignancies by providing optimal target coverage and addressing mechanisms of adaptive resistance to first generation KRASG12C inhibitors. Enrollment of patients with KRASG12C mutant non-small cell lung cancer into the ONKORAS-101 trial is expected to begin in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) has dosed the first child in PROPEL 3, a Phase 3 clinical trial studying the efficacy and safety of infigratinib in children with achondroplasia. The trial design has received positive feedback from the U.S. FDA and the EU EMA. Data from PROPEL 2's Phase 2 clinical trial showed promising results, supporting infigratinib's potential as an oral, well-tolerated treatment option. BridgeBio expects to begin development of infigratinib in hypochondroplasia by initiating an observational lead-in study in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) granted 147,373 shares of restricted stock units to thirty new employees, with vesting schedules and conditions outlined. The awards were made under the Amended and Restated 2019 Inducement Equity Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
-
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) has submitted an NDA for acoramidis to the U.S. FDA for the treatment of ATTR-CM. The application was based on positive results from ATTRibute-CM Phase 3 study, demonstrating a highly statistically significant result and rapid clinical benefit on the composite endpoint of ACM and CVH in patients treated with acoramidis. Acoramidis showed an 81% absolute survival rate, improvements on laboratory and functional measures, and was well-tolerated with no safety signals of potential clinical concern.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) presented additional Phase 3 data from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, at the American Heart Association Scientific Sessions 2023. The study demonstrated that acoramidis improved clinical outcomes for ATTR-CM patients, showing early and sustained benefits on survival and cardiovascular-related hospitalization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
The current stock price of Bridgebio Pharma (BBIO) is $36.85 as of February 21, 2025.
What is the market cap of Bridgebio Pharma (BBIO)?
The market cap of Bridgebio Pharma (BBIO) is approximately 7.0B.
What does BridgeBio Pharma, Inc. specialize in?
BridgeBio Pharma specializes in discovering, creating, and delivering transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers.
What are the core focus areas of BridgeBio Pharma's pipeline?
The core focus areas include Mendelian diseases, Genetic Dermatology, Oncology, and Gene Therapy.
What are some key programs in BridgeBio's pipeline?
Key programs include acoramidis (AG10) for ATTR-CM, infigratinib for achondroplasia and hypochondroplasia, and BBP-418 for LGMD2I/R9.
What recent financial achievements has BridgeBio Pharma accomplished?
BridgeBio recently completed a $200 million private financing for its oncology subsidiary and has conducted multiple public offerings.
Has BridgeBio Pharma formed any significant partnerships?
Yes, BridgeBio has partnered with global pharmaceutical leaders like Bayer for the commercial development and distribution of key assets.
What recent clinical trial results has BridgeBio Pharma announced?
BridgeBio announced positive results from the Phase 3 ATTRibute-CM trial for acoramidis, showing significant improvements in health-related quality of life for patients with ATTR-CM.
When was BridgeBio Pharma founded?
BridgeBio Pharma was founded in 2015.
Where is BridgeBio Pharma headquartered?
BridgeBio Pharma is headquartered in Palo Alto, California.
What is the therapeutic approach of BridgeBio Pharma?
BridgeBio Pharma applies a systematic mapping of the genetic disease landscape to identify promising therapeutic assets and leverages its proprietary platform to develop these assets into impactful treatments.
How can I learn more about BridgeBio Pharma’s developments?
For more information, visit bridgebio.com and follow BridgeBio on LinkedIn and Twitter.
Bridgebio Pharma
NYSE:BBIO
BBIO Rankings
BBIO Stock Data
6.96B
150.77M
2.92%
92.29%
10.79%
Biotechnology
Pharmaceutical Preparations
United States
PALO ALTO